خدمات علاج الإدمان

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. A Study to Evaluate Smartphone-based Digital Phenotyping for Relapse Prediction in Alcohol-associated Liver Disease

   Rochester, Minn.

   The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients with alcohol-associated liver disease.

   The secondary aim of this study is to assess the relationship between this digital phenotype and markers of disease severity outcome, including MELD score and readmission rates.

2. A Study to Evaluate AAV8-human Cocaine Hydrolase to Treat Cocaine Use Disorder

   Rochester, Minn.

   The purpose of this study is to see if an experimental agent, when given to subjects who wish to abstain from cocaine, will decrease their craving for cocaine and prevent them from relapsing and returning to cocaine use.  This experimental agent is called AAV8-hCocH; and it is a gene modified viral vector.  We want to determine the safety of its use in adults who have a cocaine use disorder in sustained remission.  

3. Attitudes and Beliefs About Gene Transfer Therapy in Adults with Cocaine Use Disorder

   Rochester, Minn.

   The purpose of this study is to investigate the facilitators and barriers of adults with a history of cocaine use disorder (CocUD) in sustained remission to participating in a Phase I gene transfer study aimed at reducing the rate of cocaine relapse. 

4. A Study to Evaluate the Safety, Tolerability and Effectiveness of V117957 in Subjects with Insomnia Associated with Alcohol Cessation

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, tolerability and effectiveness of V117957, compared to placebo, in subjects with alcohol use disorder (AUD) who experience insomnia associated with alcohol cessation.

5. A Study to Analyse the Genetic Makeup of Those with Opioid and Substance Use Disorders

   Rochester, Minn., Albert Lea, Minn.

   The purpose of this study is to establish an opioid and multiple addiction (OMA) biobank that creates a comprehensive standard patient phenotype using standardized subjective assessments and objective behavioral measurements for future research.